Pioneering The Next
Generation 
Of Targeted
Psychoative Medications

  • SOCIAL ICONS – 6
  • SOCIAL ICONS – 7
  • SOCIAL ICONS – 5
  • SOCIAL ICONS – 9
  • SOCIAL ICONS – 8
Artboard – 2_2x.png

3 Primary Breakthroughs For The Treatment Of Mental Health Issues.

01.

Discovered an efficient, patent-pending bacterial biosynthesis process for tryptamine production.

02.

Developing a portfolio of tryptamine-derived, psychedelically inspired molecules.

03.

Demonstrated the entourage effect of certain tryptamines in a laboratory-controlled environment.

Artboard – 4_2x.png

Paradigm Shift For Treating Mental Illness and Neurological Disorders

PsyBio Therapeutics is developing biosynthetic psychoactive compounds which offer a new paradigm of treatment to reverse the course of mental health issues.

Artboard – 5_2x.png

PsyBio’s Objective Is to Develop Ground-Breaking Patient Treatments Based Upon Psychedelic Agents

PsyBio Therapeutics is creating a portfolio of unique, scientifically developed, psychoactive compounds as potential therapeutic agents for mental and neurologic health issues and developing an efficient, patent-pending bacterial biosynthesis process for tryptamine production with platform technology utilizing metabolic engineering and optimization techniques.

Bullet_2x.png

Research & Development Partners

Miami University, Oxford, OH

Bullet_2x.png

Manufacturing

Curia Global
Biose Industrie
Berkeley Lab

Bullet_2x.png

Analyst Coverage

Maxim Group
Noble Capital Markets

Artboard – 7_2x.png

Industry Comparables

The antidepressant drug market was valued at USD 13.39 billion in 2018 and is expected to reach USD 15.88 billion by 2025

Market Cap. / Est. Valuation

Not Disclosed

$1.7B

$1.8B

$218M

$287M

$251M

Symbol

N/A

NASDAQ | CMPS

NEO | MMED

NEO | CYBN

TSX-V | NUMI

CSE | FTRPF

Company Name

ATAI Life Sciences

COMPASS Pathways

MindMed

Cybin Corp

Numinis Wellness

FieldTrip

Send Us a Message

 

Investor Inquiries